[Treatment of endometriosis. Evaluation of preoperative therapy with danazol, gestrinone and buserelin (nasal spray and implant)]. 1990

M Nisolle, and F Clerckx, and F Casanas-Roux, and S Gillerot, and D Bourgonjon, and J Donnez
Department of Gynecology, Cliniques Universitaires St. Luc, Brussels, Belgium.

In order to adequately assess the effectiveness of danazol, gestrinone, buserelin-nasal spray (IN) and buserelin-implant (SC), a prospective non randomized study was initiated in 178 patients with laparoscopically confirmed ovarian endometriosis. After hormonal therapy, laparotomy with microsurgical resection of endometriotic cysts or laparoscopy laser was carried out. Regression (greater than 25%) of ovarian endometriosis was noted in 30, 34, 73 and 91% of cases after danazol, gestrinone and buserelin IN and buserelin SC respectively. Histological study proves that hormonal treatment leads to an incomplete suppression of ovarian endometriotic implants and this suggests the necessity to remove surgically invasive ovarian endometriosis. The pregnancy rate in moderate endometriosis (55%) differed significantly from the rate obtained in severe endometriosis (44%). The highest percentages were found after buserelin therapy. In conclusion, preoperative use of a potent GnRH agonist, administered subcutaneously, seems to be the best therapeutic approach when associated to surgery (CO2 laser or microsurgery).

UI MeSH Term Description Entries
D011300 Preoperative Care Care given during the period prior to undergoing surgery when psychological and physical preparations are made according to the special needs of the individual patient. This period spans the time between admission to the hospital to the time the surgery begins. (From Dictionary of Health Services Management, 2d ed) Care, Preoperative,Preoperative Procedure,Preoperative Procedures,Procedure, Preoperative,Procedures, Preoperative
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D002064 Buserelin A potent synthetic analog of GONADOTROPIN-RELEASING HORMONE with D-serine substitution at residue 6, glycine10 deletion, and other modifications. Bigonist,Buserelin Acetate,HOE-766,Profact,Receptal,Suprecur,Suprefact,Tiloryth,Acetate, Buserelin,HOE 766,HOE766
D003613 Danazol A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders. Azol,Cyclomen,Danatrol,Danazant,Danazol-Ratiopharm,Danocrine,Danol,Danoval,Ladogal,Norciden,Panacrine,Danazol Ratiopharm
D004715 Endometriosis A condition in which functional endometrial tissue is present outside the UTERUS. It is often confined to the PELVIS involving the OVARY, the ligaments, cul-de-sac, and the uterovesical peritoneum. Endometrioma,Endometriomas,Endometrioses
D005260 Female Females
D005867 Gestrinone A non-estrogenic contraceptive which is a weak progestin with strong anti-progesterone properties. It is effective if used once a week orally or can also be used in intravaginal devices. 18,19-Dinorpregna-4,9,11-trien-20-yn-3-one, 13-ethyl-17-hydroxy-, (17alpha)-,Dimetriose,Nemestran,R-2323,R2323,R 2323
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000281 Administration, Intranasal Delivery of medications through the nasal mucosa. Drug Administration, Intranasal,Administration, Intranasal Drug,Administration, Nasal,Intranasal Administration,Intranasal Drug Administration,Administrations, Intranasal,Administrations, Intranasal Drug,Administrations, Nasal,Drug Administrations, Intranasal,Intranasal Administrations,Intranasal Drug Administrations,Nasal Administration,Nasal Administrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

M Nisolle, and F Clerckx, and F Casanas-Roux, and S Gillerot, and D Bourgonjon, and J Donnez
January 1990, International journal of fertility,
M Nisolle, and F Clerckx, and F Casanas-Roux, and S Gillerot, and D Bourgonjon, and J Donnez
May 1989, Fertility and sterility,
M Nisolle, and F Clerckx, and F Casanas-Roux, and S Gillerot, and D Bourgonjon, and J Donnez
April 1988, Nihon Sanka Fujinka Gakkai zasshi,
M Nisolle, and F Clerckx, and F Casanas-Roux, and S Gillerot, and D Bourgonjon, and J Donnez
April 2006, Fertility and sterility,
M Nisolle, and F Clerckx, and F Casanas-Roux, and S Gillerot, and D Bourgonjon, and J Donnez
January 1993, International journal of fertility and menopausal studies,
M Nisolle, and F Clerckx, and F Casanas-Roux, and S Gillerot, and D Bourgonjon, and J Donnez
January 1992, Human pathology,
M Nisolle, and F Clerckx, and F Casanas-Roux, and S Gillerot, and D Bourgonjon, and J Donnez
October 1989, American journal of obstetrics and gynecology,
M Nisolle, and F Clerckx, and F Casanas-Roux, and S Gillerot, and D Bourgonjon, and J Donnez
January 1993, Reproduction, fertility, and development,
M Nisolle, and F Clerckx, and F Casanas-Roux, and S Gillerot, and D Bourgonjon, and J Donnez
December 1986, European journal of obstetrics, gynecology, and reproductive biology,
M Nisolle, and F Clerckx, and F Casanas-Roux, and S Gillerot, and D Bourgonjon, and J Donnez
July 1990, Obstetrics and gynecology,
Copied contents to your clipboard!